A Phase 2 interventional study of FYU-981 and Placebo in Hyperuricemia, sponsored by Fuji Yakuhin Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-02-14.
Sponsored by Fuji Yakuhin Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing dotinurad in Hyperuricemia — 3 open to participants now, 3 under way, 2 of them phase 3. dotinurad · Hyperuricemia.
Among the 11 studies testing dotinurad in Hyperuricemia, this one is the 7th largest by planned enrollment, is the only one that started in 2015, is one of 3 in phase 2, and was the 2nd registered.
240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.
Browse Hyperuricemia studies →3 of the 11 studies testing dotinurad in Hyperuricemia are open now, in 4 countries. Recruiting first, the newest first:
Crystalys Therapeutics · Sites in United States
Ages 18–75
Crystalys Therapeutics · Sites in United States, Poland, Spain
Ages 18–75
Saga University · Sites in Japan
Ages 20+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Hyperuricemia studies recruiting now, 8 (28%) set no upper age limit and 13 (45%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 5 · Phase 4 1
First in 2014; this study’s year is marked. 1 started in 2015.
This study's planned enrollment of 200 is above the median of 68 across 193 interventional studies indexed under Hyperuricemia.
Median enrollment 201 across the 11 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 5 most frequent:
Fuji Yakuhin Co., Ltd. is the lead sponsor of 12 studies on the registry; none are open to participants now.
Fuji Yakuhin Co., Ltd. has 5 studies filed under Hyperuricemia — fewer than ten, so there is no comparison to draw.
2 of the studies testing dotinurad in Hyperuricemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07089875Phase 3Crystalys TherapeuticsA Study of Dotinurad Versus Allopurinol in Participants With Gout | 2027-11-29 |
| NCT06834230Saga UniversityEffect of Dotinurad in Hyperuricemia With Hypertension | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies testing dotinurad in Hyperuricemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is confirmatory investigation of safety and efficacy (dose response and optimal dose according to the percent reduction from baseline in serum urate level at the final visit) of FYU-981 administered orally to hyperuricemic patients with and without gout for 12 weeks (dose-escalating initial period: 4 weeks followed by maintenance period: 8 weeks) by the method of randomized (dynamic allocation), placebo-controlled, double-blind, parallel group comparison.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
>= 7.0mg/dL in patients with history of gout, or >= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or >= 9.0mg/dL
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: FYU-981 High dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
Drug: FYU-981
Drug: FYU-981 High middle dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 High middle dose arm receive active drug, FYU-981 High middle dose.
Drug: FYU-981
FYU-981 Middle dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
Drug: FYU-981
Drug: FYU-981 Low dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
Drug: FYU-981
Drug: Placebo, (Oral daily dosing for 12 weeks) Subjects randomized to the placebo arm receive placebo.
Drug: Placebo
Percent reduction from baseline in serum urate level at the final visit
Time frame: 12 weeks
The record gives a start of May 2015, a primary completion of May 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dotinurad
Fuji Yakuhin Co., Ltd.